Fresh laws on the regulation of medicines are working their way through the US Congress — but will they strike the right balance between public safety and innovation? Meredith Wadman investigates.
This is a preview of subscription content, log in via an institution to check access.
Related links
Related links
Related links in Nature Research
Experts call for active surveillance of drug safety
Related external links
Pharmaceutical Research and Manufacturers of America
Rights and permissions
About this article
Cite this article
Moment of reckoning. Nature 446, 844–845 (2007). https://doi.org/10.1038/446844a
Published:
Issue Date:
DOI: https://doi.org/10.1038/446844a
- Springer Nature Limited
This article is cited by
-
FDA poised for broader powers over drugs on sale
Nature (2007)
-
In brief
Nature (2007)